Stock news
10 stories match “IOT”
- Market narrative auditsBiotech2k buys into Vertiv after its shares leapt in the session after resultsRevenue jumped 61.2% and guidance of about $4.41 billion sits about 2.3% above the quarter, but shares trade at 67.2 times trailing earnings. VRT ·
Market narrative auditsKrystal Biotech, Inc. (NASDAQ: KRYS) Reports Early KB113 Tumor ResponsesLesions regressed in all three treated patients, including tumors that were not injected. The sample is too small and uncontrolled to establish durable efficacy. KRYS ·
Investor guidesTwilio Inc. (NYSE: TWLO) Stock Is Down 11%: The Investment CaseOrganic growth and cash flow are improving, but the valuation still requires Twilio to defend its communications platform from carrier costs and cheaper alternatives. TWLO ·
Market narrative auditsBiotech2k Maps Insmed Incorporated (NASDAQ: INSM) TPIP Patent PathBiotech2k's patent test meets a live Phase 3 program: Insmed Incorporated (NASDAQ: INSM) has started three of four PALM studies, but rival patents reach 2042. INSM ·
Market narrative auditsBiotech2k Tests Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)'s FOP UpsideBiotech2k says Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)'s Atebrioz is medically useful but financially modest. The patient pool, licensing costs and an existing rival explain why. MIRM ·
Market narrative auditsCan CoreWeave, Inc. (NASDAQ: CRWV)'s Biotech Deal Matter?Harell Data brings a new biotech workload, but the release omits contract value, capacity and minimum spend. A 1% test shows the missing bar. CRWV ·
Investor guidesBraveheart Bio, Inc. (NASDAQ: BRVE) Stock Is Down 14%: The Investment CaseThe selloff leaves a newly public biotech valued near $2.3 billion before its only drug has produced global Phase 3 data. BRVE ·
Market narrative auditsBiotech2k Tests Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Pipeline MathBiotech2k argues that GLP-1 and siRNA combinations could shift, not add, sales. Company data show why a larger franchise could still make the math work. MDGL ·
Market narrative auditsBiotech2k Tests Cogent Biosciences, Inc. (NASDAQ: COGT) Safety FearBiotech2k separates laboratory results from a broader liver-safety signal. Cogent's new FDA milestone does not settle the eventual label. COGT ·
Investment case changesSamsara's Biggest Customers Drive Growth as Margins ImproveSamsara's largest customers grew recurring revenue more than 50%. Both reported and adjusted operating margins improved, strengthening the profit case. IOT ·

